Crescent Biopharma announced it will present the ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for multiple solid tumors, at the 2026 ASCO Annual Meeting. The global trial is enrolling up to 290 patients with cancers like NSCLC, gastrointestinal, and gynecological types to evaluate safety, dosing, and preliminary effectiveness. Initial clinical data from the trial are expected starting in Q1 2027, with further combination therapy data anticipated later that year. This development aims to advance CR-001 as a potential new immuno-oncology treatment option for cancer patients worldwide.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
